^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SYS6010

    i
    Other names: CPO-301, SYS 6010, SYS-6010, SYS6010, CPO301, CPO 301
    Associations

    News

    Trials
    Company:
    CSPC Pharma
    Drug class:
    Topoisomerase I inhibitor, EGFR-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    4d
    A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2 trial
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • SYS6010
    7d
    SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2 trial
    |
    Enshuxing (enlonstobart) • SYS6010
    9d
    A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. (clinicaltrials.gov)
    P2/3, N=737, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2/3 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • Enshuxing (enlonstobart) • SYS6010
    14d
    A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=444, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P1/2 trial
    |
    sirolimus • trastuzumab envedotin (DP303c) • SYS6010
    18d
    Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） (clinicaltrials.gov)
    P3, N=380, Recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • pemetrexed • SYS6010
    4ms
    A Phase Ⅰb/Ⅲ Clinical Study of SYS6010 in combination with Osimertinib in patients with locally advanced or metastatic NSCLC (ChiCTR2500106103)
    P1, N=116, Recruiting, Shanghai Chest Hospital; Shanghai Chest Hospital
    New P1 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • SYS6010
    4ms
    A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors (clinicaltrials.gov)
    P=N/A, N=25, Active, not recruiting, Fujian Cancer Hospital
    New trial
    |
    SYS6010
    6ms
    A Phase Ib/II Study on the Safety and Efficacy of SYS6010 and SYS6010 in Combination with SYH2051±Bevacizumab in Patients with Advanced Solid Tumors (ChiCTR2500100723)
    P1/2, N=138, Not yet recruiting, Sun Yat-sen University Cancer Center, Fujian Provincial Cancer Hospital; CSPC Megalith Biopharmaceutical Co., Ltd..
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR expression • EGFR positive
    |
    Avastin (bevacizumab) • SYS6010
    8ms
    A Phase Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Dosing Regimens of SYS6010 in Patients with Advanced Solid Tumors (ChiCTR2500099933)
    P1/2, N=199, Recruiting, Fujian Provincial Cancer Hospital; CSPC Megalith Biopharmaceutical Co., Ltd..
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression • EGFR positive
    |
    SYS6010
    over2years
    A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=102, Recruiting, Conjupro Biotherapeutics, Inc.
    New P1 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    EGFR mutation • KRAS wild-type • RAS wild-type
    |
    SYS6010